6533b7d3fe1ef96bd1261407

RESEARCH PRODUCT

Immunopathology of leishmaniasis: an update.

Serafino MansuetoG. Di LorenzoPasquale MansuetoEnrico CillariGiustina VitaleRini Gb

subject

Regulatory T cellImmunopathology; LeishmaniasisengT-LymphocytesImmunologyApoptosisImmunopathology03 medical and health sciences0302 clinical medicineImmune systemCutaneous leishmaniasisImmunopathologyLeishmaniasisengmedicineImmunology and AllergyAnimalsHumansLeishmaniasisPharmacologybiologybusiness.industryLeishmaniasismedicine.diseaseLeishmaniabiology.organism_classificationmedicine.anatomical_structureVisceral leishmaniasis030220 oncology & carcinogenesisImmunologybusinessCD8030215 immunology

description

Leishmaniasis represents a severe, increasing, public health problem. The perspective of its control is highly dependent on research progress, on therapeutic manipulations of the immune system, and on vaccine development. There is a correlation between the clinical outcome of Leishmania infection and the cytokine response profile. While a protective immune response against Leishmania has been clearly identified to be related to the influence of a type-1 response and IFN-γ production, the precise role of T helper (TH) 2 cytokines in non-healing infections requires further exploration. IL-4 and IL-13 (TH2 cytokines) can promote disease progression in cutaneous leishmaniasis, whereas IL-4 would appear to enhance protective type-1 responses in visceral leishmaniasis. Thus, the TH1/TH2 paradigm of resistance/susceptibility to intracellular parasites is probably an oversimplification of a more complicated network of regulatory/counter regulatory interactions. Moreover, the presence of antigen specific regulatory T cell subsets may provide an environment that contributes to the balance between TH1 and TH2 cells. Finally, the involvement of CD8+T cells has been described, but the modality of their function in this kind of infection has not been so far elucidated.

10.1177/039463200702000302https://pubmed.ncbi.nlm.nih.gov/17880757